Literature DB >> 24424313

Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.

Diane St Germain1, Andrea M Denicoff, Eileen P Dimond, Angela Carrigan, Rebecca A Enos, Maria M Gonzalez, Kathy Wilkinson, Michelle A Mathiason, Brenda Duggan, Shaun Einolf, Worta McCaskill-Stevens, Donna M Bryant, Michael A Thompson, Stephen S Grubbs, Ronald S Go.   

Abstract

PURPOSE: Screening logs have the potential to help oncology clinical trial programs at the site level, as well as trial leaders, address enrollment in real time. Such an approach could be especially helpful in improving representation of racial/ethnic minority and other underrepresented populations in clinical trials.
METHODS: The National Cancer Institute Community Cancer Centers Program (NCCCP) developed a screening log. Log data collected from March 2009 through May 2012 were analyzed for number of patients screened versus enrolled, including for demographic subgroups; screening methods; and enrollment barriers, including reasons for ineligibility and provider and patient reasons for declining to offer or participate in a trial. User feedback was obtained to better understand perceptions of log utility.
RESULTS: Of 4,483 patients screened, 18.4% enrolled onto NCCCP log trials. Reasons for nonenrollment were ineligibility (51.6%), patient declined (25.8%), physician declined (15.6%), urgent need for treatment (6.6%), and trial suspension (0.4%). Major reasons for patients declining were no desire to participate in trials (43.2%) and preference for standard of care (39%). Major reasons for physicians declining to offer trials were preference for standard of care (53%) and concerns about tolerability (29.3%). Enrollment rates onto log trials did not differ between white and black (P = .15) or between Hispanic and non-Hispanic patients (P = .73). Other races had lower enrollment rates than whites and blacks. Sites valued the ready access to log data on enrollment barriers, with some sites changing practices to address those barriers.
CONCLUSION: Use of screening logs to document enrollment barriers at the local level can facilitate development of strategies to enhance clinical trial accrual.

Entities:  

Mesh:

Year:  2014        PMID: 24424313      PMCID: PMC3948711          DOI: 10.1200/JOP.2013.001194

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  23 in total

1.  Chemotherapy drug shortages in the United States: genesis and potential solutions.

Authors:  Michael P Link; Karen Hagerty; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

2.  A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program.

Authors:  John F Scoggins; Scott D Ramsey
Journal:  J Natl Cancer Inst       Date:  2010-08-03       Impact factor: 13.506

3.  A screening tool to enhance clinical trial participation at a community center involved in a radiation oncology disparities program.

Authors:  Julian W Proctor; Elaine Martz; Larry L Schenken; Rebecca Rainville; Ursula Marlowe
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

4.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Authors:  P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

Review 5.  Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors.

Authors:  Edward J Mills; Dugald Seely; Beth Rachlis; Lauren Griffith; Ping Wu; Kumanan Wilson; Peter Ellis; James R Wright
Journal:  Lancet Oncol       Date:  2006-02       Impact factor: 41.316

6.  Physician-related factors involved in patient decisions to enroll onto cancer clinical trials.

Authors:  Robert L Comis; Jon D Miller; Diane D Colaizzi; Linda G Kimmel
Journal:  J Oncol Pract       Date:  2009-03       Impact factor: 3.840

7.  Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.

Authors:  Edward L Korn; Boris Freidlin; Margaret Mooney; Jeffrey S Abrams
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

8.  Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.

Authors:  A Kaluzny; O Brawley; D Garson-Angert; J Shaw; P Godley; R Warnecke; L Ford
Journal:  J Natl Cancer Inst       Date:  1993-12-01       Impact factor: 13.506

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

Authors:  Andrea M Denicoff; Worta McCaskill-Stevens; Stephen S Grubbs; Suanna S Bruinooge; Robert L Comis; Peggy Devine; David M Dilts; Michelle E Duff; Jean G Ford; Steven Joffe; Lidia Schapira; Kevin P Weinfurt; Margo Michaels; Derek Raghavan; Ellen S Richmond; Robin Zon; Terrance L Albrecht; Michael A Bookman; Afshin Dowlati; Rebecca A Enos; Mona N Fouad; Marjorie Good; William J Hicks; Patrick J Loehrer; Alan P Lyss; Steven N Wolff; Debra M Wujcik; Neal J Meropol
Journal:  J Oncol Pract       Date:  2013-10-15       Impact factor: 3.840

View more
  21 in total

1.  Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community.

Authors:  Eileen P Dimond; Robin T Zon; Bryan J Weiner; Diane St Germain; Andrea M Denicoff; Kandie Dempsey; Angela C Carrigan; Randall W Teal; Marjorie J Good; Worta McCaskill-Stevens; Stephen S Grubbs; Eileen P Dimond; Robin T Zon; Bryan J Weiner; Diane St Germain; Andrea M Denicoff; Kandie Dempsey; Angela C Carrigan; Randall W Teal; Marjorie J Good; Worta McCaskill-Stevens; Stephen S Grubbs
Journal:  J Oncol Pract       Date:  2015-12-01       Impact factor: 3.840

2.  Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation.

Authors:  Joseph M Unger; Dawn L Hershman; Mark E Fleury; Riha Vaidya
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

Review 3.  Barriers to accrual and enrollment in brain tumor trials.

Authors:  Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

4.  Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer.

Authors:  Justin E Bekelman; Andrea Denicoff; Jeffrey Buchsbaum
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

5.  Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients.

Authors:  Grace C Hillyer; Melissa Beauchemin; Dawn L Hershman; Moshe Kelsen; Frances L Brogan; Rossy Sandoval; Karen M Schmitt; Andria Reyes; Mary Beth Terry; Andrew B Lassman; Gary K Schwartz
Journal:  Clin Trials       Date:  2020-02-03       Impact factor: 2.486

6.  Impact of Eligibility Criteria on Participant Enrollment for a Randomized Clinical Trial of Gonorrhea Treatment.

Authors:  Jill E Long; Michael R Wierzbicki; Edward W Hook
Journal:  Sex Transm Dis       Date:  2017-06       Impact factor: 2.830

7.  Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

Authors:  Herbert H Pang; Xiaofei Wang; Thomas E Stinchcombe; Melisa L Wong; Perry Cheng; Apar Kishor Ganti; Daniel J Sargent; Ying Zhang; Chen Hu; Sumithra J Mandrekar; Mary W Redman; Judith B Manola; Richard L Schilsky; Harvey J Cohen; Jeffrey D Bradley; Alex A Adjei; David Gandara; Suresh S Ramalingam; Everett E Vokes
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

8.  Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

Authors:  Winson Y Cheung; Lindsay A Renfro; David Kerr; Aimery de Gramont; Leonard B Saltz; Axel Grothey; Steven R Alberts; Thierry Andre; Katherine A Guthrie; Roberto Labianca; Guido Francini; Jean-Francois Seitz; Chris O'Callaghan; Chris Twelves; Eric Van Cutsem; Daniel G Haller; Greg Yothers; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

9.  Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program.

Authors:  Aisha T Langford; Ken Resnicow; Eileen P Dimond; Andrea M Denicoff; Diane St Germain; Worta McCaskill-Stevens; Rebecca A Enos; Angela Carrigan; Kathy Wilkinson; Ronald S Go
Journal:  Cancer       Date:  2013-12-10       Impact factor: 6.860

10.  Creating a "culture of research" in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers Program.

Authors:  Eileen P Dimond; Diane St Germain; Lianne M Nacpil; Howard A Zaren; Sandra M Swanson; Christopher Minnick; Angela Carrigan; Andrea M Denicoff; Kathleen E Igo; Jared D Acoba; Maria M Gonzalez; Worta McCaskill-Stevens
Journal:  Clin Trials       Date:  2015-02-17       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.